Selected research
Market Structure
Global Glipizide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Glipizide market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Glipizide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Glipizide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Glipizide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Glipizide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Glipizide include CCPC, TEVA, Lukang Pharma, United Laboratories, Jumpcan, Pfizer, PIDI, Disha Pharma and Jingfeng Zhiyao, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Glipizide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Glipizide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Glipizide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Glipizide market size, projected growth trends, production technologies, key applications, and end-use industries.
Glipizide Segment by Company
CCPC
TEVA
Lukang Pharma
United Laboratories
Jumpcan
Pfizer
PIDI
Disha Pharma
Jingfeng Zhiyao
Yashica Pharma
Apotex
Glipizide Segment by Type
Glipizide Tablets
Glipizide Sustained Release Tablets
Others
Glipizide Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Glipizide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glipizide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glipizide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glipizide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Glipizide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glipizide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Glipizide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Glipizide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Glipizide Tablets
- Glipizide Sustained Release Tablets
- Others
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- CCPC
- TEVA
- Lukang Pharma
- United Laboratories
- Jumpcan
- Pfizer
- PIDI
- Disha Pharma
- Jingfeng Zhiyao
- Yashica Pharma
- Apotex
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Glipizide Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Glipizide Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Glipizide Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Glipizide Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Glipizide Market Dynamics
- 2.1 Glipizide Industry Trends
- 2.2 Glipizide Industry Drivers
- 2.3 Glipizide Industry Opportunities and Challenges
- 2.4 Glipizide Industry Restraints
3 Glipizide Market by Manufacturers
- 3.1 Global Glipizide Revenue by Manufacturers (2021-2026)
- 3.2 Global Glipizide Sales by Manufacturers (2021-2026)
- 3.3 Global Glipizide Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Glipizide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Glipizide Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Glipizide Manufacturers, Product Type & Application
- 3.7 Global Glipizide Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Glipizide Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Glipizide Players Market Share by Revenue in 2025
- 3.8.3 2025 Glipizide Tier 1, Tier 2, and Tier 3
4 Glipizide Market by Type
- 4.1 Glipizide Type Introduction
- 4.1.1 Glipizide Tablets
- 4.1.2 Glipizide Sustained Release Tablets
- 4.1.3 Others
- 4.2 Global Glipizide Sales by Type
- 4.2.1 Global Glipizide Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Glipizide Sales by Type (2021-2032)
- 4.2.3 Global Glipizide Sales Market Share by Type (2021-2032)
- 4.3 Global Glipizide Revenue by Type
- 4.3.1 Global Glipizide Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Glipizide Revenue by Type (2021-2032)
- 4.3.3 Global Glipizide Revenue Market Share by Type (2021-2032)
5 Glipizide Market by Application
- 5.1 Glipizide Application Introduction
- 5.1.1 Hospital Pharmacies
- 5.1.2 Online Pharmacies
- 5.1.3 Retail Pharmacies
- 5.2 Global Glipizide Sales by Application
- 5.2.1 Global Glipizide Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Glipizide Sales by Application (2021-2032)
- 5.2.3 Global Glipizide Sales Market Share by Application (2021-2032)
- 5.3 Global Glipizide Revenue by Application
- 5.3.1 Global Glipizide Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Glipizide Revenue by Application (2021-2032)
- 5.3.3 Global Glipizide Revenue Market Share by Application (2021-2032)
6 Global Glipizide Sales by Region
- 6.1 Global Glipizide Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Glipizide Sales by Region (2021-2032)
- 6.2.1 Global Glipizide Sales by Region (2021-2026)
- 6.2.2 Global Glipizide Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Glipizide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Glipizide Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Glipizide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Glipizide Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Glipizide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Glipizide Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Glipizide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Glipizide Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Glipizide Revenue by Region
- 7.1 Global Glipizide Revenue by Region
- 7.1.1 Global Glipizide Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Glipizide Revenue by Region (2021-2026)
- 7.1.3 Global Glipizide Revenue by Region (2027-2032)
- 7.1.4 Global Glipizide Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Glipizide Revenue (2021-2032)
- 7.2.2 North America Glipizide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Glipizide Revenue (2021-2032)
- 7.3.2 Europe Glipizide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Glipizide Revenue (2021-2032)
- 7.4.2 Asia-Pacific Glipizide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Glipizide Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Glipizide Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CCPC
- 8.1.1 CCPC Company Information
- 8.1.2 CCPC Business Overview
- 8.1.3 CCPC Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CCPC Glipizide Product Portfolio
- 8.1.5 CCPC Recent Developments
- 8.2 TEVA
- 8.2.1 TEVA Company Information
- 8.2.2 TEVA Business Overview
- 8.2.3 TEVA Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 TEVA Glipizide Product Portfolio
- 8.2.5 TEVA Recent Developments
- 8.3 Lukang Pharma
- 8.3.1 Lukang Pharma Company Information
- 8.3.2 Lukang Pharma Business Overview
- 8.3.3 Lukang Pharma Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Lukang Pharma Glipizide Product Portfolio
- 8.3.5 Lukang Pharma Recent Developments
- 8.4 United Laboratories
- 8.4.1 United Laboratories Company Information
- 8.4.2 United Laboratories Business Overview
- 8.4.3 United Laboratories Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 United Laboratories Glipizide Product Portfolio
- 8.4.5 United Laboratories Recent Developments
- 8.5 Jumpcan
- 8.5.1 Jumpcan Company Information
- 8.5.2 Jumpcan Business Overview
- 8.5.3 Jumpcan Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Jumpcan Glipizide Product Portfolio
- 8.5.5 Jumpcan Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Glipizide Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 PIDI
- 8.7.1 PIDI Company Information
- 8.7.2 PIDI Business Overview
- 8.7.3 PIDI Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 PIDI Glipizide Product Portfolio
- 8.7.5 PIDI Recent Developments
- 8.8 Disha Pharma
- 8.8.1 Disha Pharma Company Information
- 8.8.2 Disha Pharma Business Overview
- 8.8.3 Disha Pharma Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Disha Pharma Glipizide Product Portfolio
- 8.8.5 Disha Pharma Recent Developments
- 8.9 Jingfeng Zhiyao
- 8.9.1 Jingfeng Zhiyao Company Information
- 8.9.2 Jingfeng Zhiyao Business Overview
- 8.9.3 Jingfeng Zhiyao Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Jingfeng Zhiyao Glipizide Product Portfolio
- 8.9.5 Jingfeng Zhiyao Recent Developments
- 8.10 Yashica Pharma
- 8.10.1 Yashica Pharma Company Information
- 8.10.2 Yashica Pharma Business Overview
- 8.10.3 Yashica Pharma Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Yashica Pharma Glipizide Product Portfolio
- 8.10.5 Yashica Pharma Recent Developments
- 8.11 Apotex
- 8.11.1 Apotex Company Information
- 8.11.2 Apotex Business Overview
- 8.11.3 Apotex Glipizide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Apotex Glipizide Product Portfolio
- 8.11.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Glipizide Value Chain Analysis
- 9.1.1 Glipizide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Glipizide Production Mode & Process
- 9.2 Glipizide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Glipizide Distributors
- 9.2.3 Glipizide Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst